WCRD 2025 CV Shiv K. Singh

Professor Shiv Singh

Mildred-Scheel Endowed Professor at the Department of Gastroenterology Gastrointestinal Oncology & Endocrinology, UMG, University Medical Center Gottingen (UMG)

https://orcid.org/0000-0002-5725-4058

Qualifications and Career

2002-2004 Master of Science in Biochemistry, University of Bundelkhand, India

Doctorate

2006-2010 Dr. rer. physiol („summa cum laude”), Philipps-University of Marburg

Academic & Professional Experience

Since 2022 Extension of Max-Eder Group Leader position, Department of

Gastroenterology, Gastrointestinal Oncology and Endocrinology, UMG

Since 2018 Max-Eder Group Leader, Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, UMG

2016-2017 Junior Group Leader, Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, UMG

2014-2016 Postdoctoral Fellow at Barrow Neurological Institute, Phoenix, USA

2011-2014 Postdoctoral Fellow at Philipps-University of Marburg

Engagement in the Research System

Since 2023 Appointed as Editorial board member for the Journal of Biological Chemistry (JBC)

Since 2023 Scientific board member of the American Society for Biochemistry and Molecular

Biology (ASBMB)

Since 2021 Faculty and advisory committee member of the International Max Planck Research School for Genome Science graduate school (IMPRS-GS)

Since 2019 PI in the Clinician Scientist Program „Cell Dynamics in pathogenesis and therapy” at the UMG Promotionskolleg for MD students

Since 2018 Faculty and examination committee member of the University of Gottingen graduate Schools (GGNB, GAUSS, DNB and UMG)

Five most important recent publications

1. Urbach L, Wieland L, Penz F, Samuel RD, Kuffer S, Klein L, Lenz C, Sax U, Ghadimi M, Schulz- Heddergott R, Hessmann E, Ellenrieder V, Dusetti N, Singh SK (2025). TP53 missense- specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Science Advances,11(27):2339.
2. Klein L, Tu M, Krebs N, Urbach L, Grimm G, Umair L, Penz F, Blandau A, Xueyan Wu, Samuel RD, Kuffer S, Wegwitz F, Chan N, Aliar K, Vyas F, Kishore U, Hessmann E, Trumpp A, Espinet E, Papantonis A, Khokha R, Ellenrieder V, Grunwald BT, Singh SK (2025). Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Nature Communications,16(1):335
3. Espinet E, Klein L, Puré E, Singh Sk (2022). Mechanisms of PDAC subtype heterogeneity and therapy response. Trends in Cancer,12:1060-1071.
4. Krebs N, Klein L, Wegwitz F, Espinet E, Maurer C, Tu M, Xu X, Kuffer S, Bohnenberger H, Cameron S, Bruner M, Neesse A, Kishore U, Hessmann E, Trumpp A, Strobel P, Brekken R, Ellenrieder V, Singh SK (2022). Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer. JCI Insight, 16:e154475

5. Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Xiaojuan L, Urbach L, Danieli-Mackay A, Kuffer S, Bojarczuk K, Mizi A, Gunesdogan U, Chapuy B, Gu Z, Kishore U, Neesse A, Strobel P, Hessmann E, Hahn SA, Trumpp A, Papantonis A, Ellenrieder V, Singh SK (2021). TNFa-producing Macrophages Determine Subtype Identity and Prognosis via AP1 Enhancer Reprogramming in Pancreatic Cancer. Nature Cancer,2:1185-1203

Academic Distinctions

2022 Go-VIP award for JCI Insight publication, PMID: 35993361

2020 Best lecture feedback in the entire MSc Molecular-Medicine program, UMG

2019 Mildred-Scheel Fellow award at the 9th Mildred Scheel Conference, Bonn

2014 National scholar award, UEGW, Vienna

2014 Basic Science Abstract Award, UeGW, Vienna

2013 Fellowship grant from European Cancer Congress, Amsterdam

2013 Travel Award from European Pancreatic Club, Zurich

2010 Meeting Bursary Award from Cold Spring Harbor Laboratory, New York

2009 Travel Award from Salk Institute for Biological Sciences, San Diego